View Older Stories View More Recent Stories
-
RBC Capital Starts Becton Dickinson (BDX) at Sector Perform, '"New BD" Holds Potential Post Business Separation in CQ1'26'
-
BD partners with Henry Ford Health on pharmacy automation system
-
Starboard Releases 13F, Shows Two New Stakes
-
Becton Dickinson (BDX) PT Raised to $200 at Piper Sandler
-
Becton Dickinson (BDX) Tops Q3 EPS by 28c, Beats on Revenue; Offers FY25 EPS Guidance
-
BD to invest $35 million in Nebraska facility expansion
-
BD receives FDA clearance for rapid COVID-19 test
-
BD begins first pharma-sponsored trial for Libertas wearable injector
-
Becton Dickinson (BDX) Declares $1.04 Quarterly Dividend; 2.3% Yield
-
TD Cowen Reiterates Hold Rating on Becton Dickinson (BDX)
-
Waters to merge with BD's biosciences unit in $17.5 billion deal
-
BD names Bilal Muhsin as executive vice president and president of new segment
-
Increasing unusual option volume: VEA HUYA AMKR NTRS BLNK BDX
-
Increasing unusual put option volume: BDX SATS FE GTLB IEP PLCE INSM PLAY PCG IRBT IQ ETHA
-
Stifel Reiterates Buy Rating on Becton Dickinson (BDX)
-
Stifel Reiterates Buy Rating on Becton Dickinson (BDX)
-
Becton Dickinson (BDX) PT Lowered to $241 at Barclays
-
Piper Sandler Highlights 'Best Value Stocks' in Medical Technology
-
Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick
-
Citi Downgrades Becton Dickinson (BDX) to Neutral
-
Wall Street analysts downgrade Becton Dickinson as 'confidence eroded'
-
Becton Dickinson (BDX) PT Lowered to $255 at Jefferies
-
Raymond James Downgrades Becton Dickinson (BDX) to Market Perform, 'Lower Growth Warrants Lower Rating'
-
Piper Sandler Downgrades Becton Dickinson (BDX) to Neutral
-
Goldman Sachs Downgrades Becton Dickinson (BDX) to Neutral
-
Becton Dickinson (BDX) PT Lowered to $224 at Stifel
-
Becton Dickinson (BDX) call put ratio 1 call to 1.2 puts on active option volume of 7800 contracts as share price down 15.7%
-
BofA Securities Downgrades Becton Dickinson (BDX) to Neutral
-
Becton Dickinson (BDX) Tops Q2 EPS by 7c; offers guidance
-
Becton Dickinson (BDX) Declares $1.04 Quarterly Dividend; 2% Yield
-
Becton Dickinson (BDX) PT Lowered to $260 at Piper Sandler
-
Becton Dickinson (BDX) Launches Bioabsorbable Mesh Designed for Umbilical Hernia Repair
-
Becton Dickinson (BDX) Appoints Gregory J. Hayes to its Board
-
Becton Dickinson (BDX) Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE Scaffold in Breast Implant Revision Surgery
-
BofA Comments on Trump and Mexico Tariff Delay Impact to Medical Technology Names
-
Increasing unusual put option volume: BDX DBX NXE IVZ NXE HLF GXO BMBL
-
Becton Dickinson (BDX) Tops Q1 EPS by 44c (from yesterday)
-
After-hours movers: Ford Motor, Qualcomm, Align Technology and more
-
Becton Dickinson (BDX) to Separate Biosciences and Diagnostic Solutions Business
-
Becton Dickinson (BDX) Said To Mull Life Sciences Segment Separation - Bloomberg
-
Becton Dickinson (BDX) Announces Share Buyback, Declares Dividends
-
Becton Dickinson (BDX) PT Raised to $280 at Piper Sandler Amid Potential Life Sciences Spin-Off'
-
Becton Dickinson (BDX) Boosts U.S. Manufacturing of Critical Medical Devices
-
Becton Dickinson (BDX) names Pamela Spikner CAO and controller
-
Increasing unusual call option volume: QUBT KULR NGD AISP MVST PRGO CRC RGTI QBTS BDX
-
Becton Dickinson (BDX) and Babson Diagnostics Launch Innovative Fingertip Blood Testing to Health Care Organizations
-
SEC: Becton Dickinson (BDX) to Pay $175M for misleading investors
-
KeyBanc on ICU Medical (ICUI): 'Survey suggests potential market share gains for ICUI'
-
Barclays highlights most and least sensitive MedTech stocks to changes in surgical volumes
-
Becton Dickinson (BDX): First of Its Kind HPV Self-Collection Study Launched to Improve Cervical Cancer Screening in Underserved Communities
